Basilea Pharmaceutica (FRA:PK5) Asset Turnover: 0.49 (As of Dec. 2025)


FRA:PK5 Basilea Pharmaceutica Ltd FRA:PK5
61 GF Score
Price €60.00
GF Value €63.56
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Asset Turnover?

Basilea Pharmaceutica FRA:PK5 +5.26% 61 Asset Turnover is 0.49 as of Dec. 2025. GuruFocus rates FRA:PK5 with a GF Score™ of 61/100 and a GF Value™ of €63.56 (Fairly Valued). The stock has 4 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Basilea Pharmaceutica's Revenue for the six months ended in Dec. 2025 was €137.6 Mil. Basilea Pharmaceutica's Total Assets for the quarter that ended in Dec. 2025 was €283.8 Mil. Therefore, Basilea Pharmaceutica's Asset Turnover for the quarter that ended in Dec. 2025 was 0.49.

Asset Turnover is linked to ROE % through Du Pont Formula. Basilea Pharmaceutica's annualized ROE % for the quarter that ended in Dec. 2025 was 42.40%. It is also linked to ROA % through Du Pont Formula. Basilea Pharmaceutica's annualized ROA % for the quarter that ended in Dec. 2025 was 18.46%.


Basilea Pharmaceutica  (FRA:PK5) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Basilea Pharmaceutica's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=52.378/123.5445
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(52.378 / 275.244)*(275.244 / 283.7575)*(283.7575/ 123.5445)
=Net Margin %*Asset Turnover*Equity Multiplier
=19.03 %*0.97*2.2968
=ROA %*Equity Multiplier
=18.46 %*2.2968
=42.40 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Basilea Pharmaceutica's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=52.378/283.7575
=(Net Income / Revenue)*(Revenue / Total Assets)
=(52.378 / 275.244)*(275.244 / 283.7575)
=Net Margin %*Asset Turnover
=19.03 %*0.97
=18.46 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Basilea Pharmaceutica Asset Turnover Related Terms


Basilea Pharmaceutica Asset Turnover Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Asset Turnover Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.65 0.82 0.97 0.86

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.42 0.60 0.41 0.49

FRA:PK5 vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Asset Turnover falls into.


FRA:PK5
61GF Score
Basilea Pharmaceutica Ltd FRA:PK5
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Basilea Pharmaceutica's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=249.031/( (276.093+302.205)/ 2 )
=249.031/289.149
=0.86

Basilea Pharmaceutica's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=137.622/( (265.31+302.205)/ 2 )
=137.622/283.7575
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.49 mean?
Basilea Pharmaceutica (FRA:PK5) has a Asset Turnover of 0.49 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Asset Turnover too high?
Basilea Pharmaceutica's current Asset Turnover is 0.49. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Asset Turnover compare to VRTX and REGN?
Basilea Pharmaceutica's Asset Turnover of 0.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Asset Turnover is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (FRA:PK5) is currently considered Fairly Valued. The stock's GF Value™ is €63.56, compared to a current price of €60.00 — trading 5.6% below its estimated fair value. The current Asset Turnover is 0.49. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Basilea Pharmaceutica (FRA:PK5), the current Asset Turnover is 0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of €60.00 is trading 5.6% below its estimated GF Value™ of €63.56. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for FRA:PK5:

  • Asset Turnover: 0.49
  • GF Value™: €63.56 vs. price of €60.00 (5.6% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for FRA:PK5

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.00
Price
€63.56
GF Value